AstraZeneca PLC ADR Outperforms Competitors Despite Losses On The Day

Dow Jones
May 02, 2025

DJ AstraZeneca PLC ADR Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

The AstraZeneca PLC ADR $(AZN)$ shed 1.78% to $70.51 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.52% to 17,710.74 and the Dow Jones Industrial Average rising 0.21% to 40,752.96.

The ADR's fall snapped a seven-day winning streak.

AstraZeneca PLC ADR closed 19.58% short of its 52-week high of $87.68, which the company achieved on August 30th.

The ADR demonstrated a mixed performance when compared to some of its competitors Thursday, as Eli Lilly & Co. $(LLY)$ fell 11.66% to $794.10, Biogen Inc. $(BIIB)$ fell 0.12% to $120.93, and Johnson & Johnson $(JNJ)$ fell 1.18% to $154.46.

Trading volume (5.8 M) remained 426,247 below its 50-day average volume of 6.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 1, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

May 01, 2025 17:23 ET (21:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10